|
|
|
| Research progress on traditional Chinese and western medicine of prevention and treatment of heart failure based on β adrenergic receptor signaling pathway |
| SHI Tianyun1 LU Cheng2 LIU Yongming1 |
1.Department of Cardiology, Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai 201203, China;
2.Department of Cardiology, the Seventh People’s Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai 200137, China
|
|
|
|
Abstract Heart failure is the terminal stage of heart disease caused by various causes, and abnormal β adrenergic receptor signaling pathway is one of the important pathophysiological mechanisms for the occurrence and development of heart failure. Three kinds of β adrenergic receptor mediated signaling pathways and abnormal number of receptors play different pathophysiological roles in the occurrence and development of heart failure, such as β1 adrenergic receptor mediated Ca2+/calmodulin dependent protein kinase Ⅱ signaling, β2 and β3 adrenergic receptor mediated Gi protein signaling. This article mainly reviews the different pathological significance of the three β adrenergic receptor signaling pathways in heart failure, and the research progress of traditional Chinese and western medicine in the prevention and treatment of heart failure by improving β adrenergic receptor signaling.
|
|
|
|
|
|
[1] McDonagh TA，Metra M，Adamo M，et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure：Developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology （ESC）. With the special contribution of the Heart Failure Association （HFA） of the ESC [J]. Eur J Heart Fail，2022，24（1）：4-131.
[2] 中国心力衰竭中心工作报告（2021）——心力衰竭患者的诊疗现况[J].中国介入心脏病学杂志，2022，30（5）：328-336.
[3] 徐佳慧，胡世莲.慢性心力衰竭的流行病学与预防措施[J].中国临床保健杂志，2021，24（6）：721-725.
[4] Mahmood A，Ahmed K，Zhang Y. β-adrenergic receptor dese- nsitization/down-regulation in heart failure：a friend or foe? [J]. Front Cardiovasc Med，2022，9：925692.
[5] Ali DC，Naveed M，Gordon A，et al. β-adrenergic receptor，an essential target in cardiovascular diseases [J]. Heart Fail Rev，2020，25（2）：343-354.
[6] Rakib A，Eva TA，Sami SA，et al. Beta-arrestins in the trea- tment of heart failure related to hypertension：a comprehensive review [J]. Pharmaceutics，2021，13（6）：838-859.
[7] Boussi L，Frishman WH. β-arrestin as a therapeutic target in heart failure [J]. Cardiol Rev，2021，29（5）：223-229.
[8] Michel LYM，Farah C，Balligand JL. The beta3 adrenergic receptor in healthy and pathological cardiovascular tissues [J]. Cells，2020，9（12）：2584-2606.
[9] 魏天天.慢性心力衰竭患者β肾上腺素受体表达水平与室性心律失常关系的研究[D].唐山：华北理工大学，2021.
[10] Ferrero KM，Koch WJ. GRK2 in cardiovascular disease and its potential as a therapeutic target [J]. Mol Cell Cardiol，2022，172：14-23.
[11] Chen Q，Tesmer JJG. G protein-coupled receptor interactions with arrestins and GPCR kinases：The unresolved issue of signal bias [J]. J Biol Chem，2022，298（9）：102279- 102292.
[12] 李如意，刘延俊，杜荣品.心力衰竭时β3肾上腺素能受体与心律失常的研究进展[J].心血管病学进展，2020， 41（1）：51-54.
[13] Grassi G，Mancia G，Esler M. Central and peripheral sympa- thetic activation in heart failure [J]. Cardiovasc Res，2022， 118（8）：1857-1871.
[14] 柯樊，廖梦阳，邱志华，等.β肾上腺素能受体在梗死后心脏重构中作用的研究进展[J].临床心血管病杂志，2021，37（4）：298-303.
[15] Motiejunaite J，Amar L，Vidal-Petiot E. Adrenergic receptors and cardiovascular effects of catecholamines [J]. Ann Endocrinol，2021，82（3-4）：193-197.
[16] Laudette M，Formoso K，Lezoualc’h F. GRKs and Epac1 interaction in cardiac remodeling and heart failure [J]. Cells，2021，10（1）：154-171.
[17] Drazner MH，Peppel KC，Dyer S，et al. Potentiation of beta-adrenergic signaling by adenoviral-mediated gene tran- sfer in adult rabbit ventricular myocytes [J]. Clin Invest，1997，99（2）：288-296.
[18] Casey LM，Pistner AR，Belmonte SL，et al. Small molecule disruption of G beta gamma signaling inhibits the progression of heart failure [J]. Circ Res，2010，107（4）：532-539.
[19] Zhang H，Ren L，Shivnaraine RV. Targeting GPCRs to treat cardiac fibrosis [J]. Front Cardiovasc Med，2022，9：1011176.
[20] Sun X，Zhou M，Wen G，et al. Paroxetine attenuates cardiac hypertrophy via blocking GRK2 and ADRB1 interaction in hypertension [J]. J Am Heart Assoc，2021，10（1）：e016364.
[21] Ippolito M，Benovic JL. Biased agonism at β-adrenergic receptors [J]. Cell Signal，2021，80：109905.
[22] 刘通，史静怡，王利，等.β2AR激动剂通过线粒体细胞凋亡途径改善大鼠心肌缺血再灌注损伤[J].山西医科大学学报，2020，51（12）：1335-1340.
[23] Chen J，Liu J，Yuan Y，et al. Molecular mechanisms of diverse activation stimulated by different biased agonists for the β2-adrenergic receptor [J]. J Chem Inf Model，2022，62（21）：5175-5192.
[24] Xing G，Yi C，Dou P，et al. Recent progress in the development of β2 adrenergic receptor agonists： a patent review （2015-2020） [J]. Expert Opin Ther Pat，2021，31（3）：239- 246.
[25] 胡小芳，李娜，王丽，等.β3肾上腺素能受体对慢性心力衰竭大鼠心肌纤维化的影响[J].临床心血管病杂志，2015，31（4）：446-450.
[26] Ahmet I，Lakatta EG，Talan MI. Pharmacological stimulation of beta2-adrenergic receptors （beta2AR） enhances ther- apeutic effectiveness of beta1AR blockade in rodent dilated ischemic cardiomyopathy [J]. Heart Fail Rev，2005，10（4）：289-296.
[27] Bundgaard H，Axelsson A，Hartvig Thomsen J，et al. The first-in-man randomized trial of a beta3 adrenoceptor agonist in chronic heart failure：the BEAT-HF trial [J]. Eur J Heart Fail，2017，19（4）：566-575.
[28] 李佳卓，王玉丹，隋艳波，等.益气温阳、活血利水法治疗慢性心力衰竭的系统评价再评价[J].中国医药导报，2022，19（6）：118-122，146.
[29] 程丹.复方真武冲剂对心肾阳虚型心力衰竭患者IL-6、NT-pro-BNP及生活质量影响的临床研究[D].合肥：安徽中医药大学，2016.
[30] Chen Y，Guo B，Zhang H，et al. Higenamine，a dual agonist for β1- and β2-adrenergic receptors identified by screening a traditional Chinese medicine library [J]. Planta Med，2019， 85（9-10）：738-744.
[31] 于武华，钟凌云，叶协滔，等.附子不同炮制品对慢性心力衰竭大鼠β1、β2肾上腺素受体表达的影响[J].中华中医药杂志，2021，36（6）：3138-3141.
[32] Sun J，Qian H，Li X，et al. Qishen Yiqi Dripping Pill improves heart failure by up-regulation of β2-adrenergic receptor expression [J]. J Heart Valve Dis，2017，26（2）：193- 199.
[33] 魏瑾.参仙升脉口服液干预心阳虚证缓慢性心律失常大鼠的实验研究[D].沈阳：辽宁中医药大学，2016.
[34] 李园园.基于钙运作探讨丹参素钠防治缺血再灌注心功能障碍的作用及机制[D].上海：上海中医药大学，2019.
[35] 阚默，明思彤，张壮，等.基于GS/βAR/cAMP/PKA信号通路探讨蜂胶总黄酮对心肌肥厚大鼠的保护作用及分子机制[J].中华中医药杂志，2021，36（6）：3235-3239.
[36] 潘健彬.柴胡三参胶囊对缺血性心律失常大鼠心肌细胞CaMKⅡmRNA及CaMKⅡ蛋白表达的影响[D].长沙：湖南中医药大学，2019.
[37] 王赛，胡烨，包斯图.黄芩苷对扩张型心肌病大鼠心室重构、心室肌细胞凋亡及β1-AR/PKA/CaMKⅡ信号通路的影响[J].中国实验方剂学杂志，2018，24（9）：140- 144.
[38] 李思耐.基于L型钙电流研究益气药干预心力衰竭电生理重构机制[D].北京：北京中医药大学，2016. |
|
|
|
